Thomas Abrams, MD: Overall Survival Data From the HIMALAYA Trial

Dr. Abrams explains overall survival (OS) data from the HIMALAYA trial, including updated 5-year OS data. This trial showed that the STRIDE regimen (durvalumab + tremelimumab) led to improved OS in patients with unresectable hepatocellular carcinoma, compared to sorafenib monotherapy. Additionally, Dr. Abrams shares how he utilizes the STRIDE regimen in his clinical practice.